Trial Profile
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms Pomalyst PMS
- Sponsors Celgene Corporation
- 17 Nov 2023 Planned End Date changed from 8 Jun 2023 to 8 Jun 2024.
- 17 Nov 2023 Planned primary completion date changed from 8 Jun 2023 to 8 Jun 2024.
- 17 May 2018 Status changed from not yet recruiting to recruiting.